重庆医科大学汪凯的科学博客分享 http://blog.sciencenet.cn/u/Kwang02 重医感染性疾病分子生物学教育部重点实验室——汪凯的学术主页

博文

EMERG MICROBES INFEC: Obatoclax inhibits SARS-CoV-2 entry

已有 1171 次阅读 2022-1-7 14:06 |系统分类:论文交流

Title: Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro

Published in Emerging Microbes & Infections on January 06, 2022

EMI.jpg

Abstract:

Coronavirus disease 2019 (COVID-19) caused by the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has set off a global pandemic. There is an urgent unmet need for safe, affordable, and effective therapeutics against COVID-19. In this regard, drug repurposing is considered as a promising approach. We assessed the compounds that affect the endosomal acidic environment by applying human angiotensin-converting enzyme 2 (hACE2)-expressing cells infected with a SARS-CoV-2 spike (S) protein-pseudotyped HIV reporter virus and identified that obatoclax resulted in the strongest inhibition of S-protein-mediated virus entry. The potent antiviral activity of obatoclax at nanomolar concentrations was confirmed in different human lung and intestinal cells infected with the SARS-CoV-2 pseudotype system as well as clinical virus isolates. Furthermore, we uncovered that obatoclax executes a double-strike against SARS-CoV-2. It prevented SARS-CoV-2 entry by blocking endocytosis of virions through diminished endosomal acidification and the corresponding inhibition of the enzymatic activity of the endosomal cysteine protease cathepsin L. Additionally, obatoclax impaired the SARS-CoV-2 S-mediated membrane fusion by targeting the MCL-1 protein and reducing furin protease activity. In accordance with these overarching mechanisms, obatoclax blocked the virus entry mediated by different S proteins derived from several SARS-CoV-2 variants of concern such as, Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2). Taken together, our results identified obatoclax as a novel effective antiviral compound that keeps SARS-CoV-2 at bay by blocking both endocytosis and membrane fusion. Our data suggested that obatoclax should be further explored as clinical drug for the treatment of COVID-19.


Full texthttps://www.tandfonline.com/doi/full/10.1080/22221751.2022.2026739 



https://m.sciencenet.cn/blog-446272-1319958.html

上一篇:新冠病毒变种B.1.640.1和B.1.640.2
下一篇:CMI: Increased immune escape of SARS-CoV-2 Omicron variant

0

评论 (0 个评论)

数据加载中...

Archiver|手机版|科学网 ( 京ICP备07017567号-12 )

GMT+8, 2022-6-26 19:14

Powered by ScienceNet.cn

Copyright © 2007- 中国科学报社

返回顶部